Optic Nerve Head Quantification While Reducing Elevated Intracranial Pressure
NCT ID: NCT02558309
Last Updated: 2017-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2015-10-31
2017-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ocular Screening in Children and Young Adults at Risk for Increased Intracranial Pressure
NCT03286426
Measurement of Optic Nerve Sheath in Traumatic Raised Intracranial Pressure
NCT00783809
Non-Invasive and Non-Contact Intracranial Pressure Waveform Recording Using Dynamic Video Ophthalmoscopy
NCT04046523
Ocular Perfusion in Patients With Idiopathic Intracranial Hypertension
NCT06545981
Optic Nerve Stimulation To Prevent Visual Deficits After Endoscopic Cranial Approaches
NCT06495580
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The goal of this study is to examine in-vivo the effect of intraocular (IOP) and intracranial pressures (ICP) on the optic nerve head (ONH).
Specific Aims:
In this study, the investigators will quantify the structural changes in the ONH in subjects with elevated ICP while they are treated to reduce the elevated pressure. This process will occur in a stepwise fashion over a period of time determined by the clinical treatment plans. The investigators will apply controlled pressures to the eye during each step of ICP lowering while OCT images are obtained.
Background:
The effect of ICP on eye health has been an area of concrete research effort in recent years. The ability to acquire non-invasive and highly detailed information on both the eye and the brain using technologies such as magnetic resonance imaging (MRI) and optical coherence tomography (OCT) have paved the way to assess non-invasively the effect of ICP in-vivo.
The ONH separates two pressurized compartments: the eyeball and the central nervous system. Situations in which ICP is elevated are often associated with papilledema, though the magnitude and the rate of change in ONH elevation in response to increased ICP or the reduction in ONH elevation in response to ICP treatments are yet to be determined. On the opposite side, glaucoma is a leading cause of blindness where elevated IOP is the leading risk factor, with clinical evidence suggesting the presence of ICP below the normal level in these subjects. The impaired balance between IOP and ICP leads to the deformation of the ONH, which triggers strangulation of the retinal ganglion cell axons when trespassing through the lamina cribrosa within the ONH on their way from the eye to the brain, leading to gradual axonal loss and irreversible visual impairment.
Significance:
Little is known about how the interaction of IOP and ICP pressure changes affect the macrostructure and microstructure of the optic nerve head structure. This information has a significant impact both for neurosurgical conditions with elevated ICP along with ocular conditions such as glaucoma and papilledema. The ability to gauge non-invasively changes in ICP will have a tremendous impact on neurosurgical management as it eliminates the need of longitudinal invasive measurements of ICP. The study will also improve the investigator's understanding of the pathophysiologic processes that lead to development of glaucoma as well as the response to treatment for subjects with papilledema. A better understanding of these processes will ultimately lead to improved detection and management of these conditions and a better understanding of ocular bio-mechanics.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intracranial Pressure Reduction
Subjects scheduled to undergo gradual, step-wise reduction of Intracranial Pressure (ICP) will be screened.
* The Glasgow Coma Scale will be administered to ascertain the cognitive ability of the participant.
* A slit lamp examination and indirect ophthalmoscopy will be performed.
Experimental:
* The subject's eye will be held open with an eye speculum during the exam.
* Another eye exam, which includes a slit lamp examination and indirect ophthalmoscopy, will be performed.
* Intraocular Pressure will be measured.
* An Optic Coherence Tomography (OCT) will be performed.
* At each step along the process of ICP reduction, the eye exam, IOP \& OCT will be performed.
Optional:
* The Ophthalmology study team will raise the IOP using an Ophthlmodynanometer. It will be raised to 20 mmHg and 40 mmHg while OCT scans are obtained.
* OCT scans will be taken at pre-manipulation, 20mmHg, 40mmHg, and post-manipulation at each step of the ICP lowering procedure.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with an external ventricular drain (EVD).
* Normally appearing eye as determined during the screening clinical examination.
Exclusion Criteria
* Ocular disorders that could affect retinal function such as retinal detachment, diabetic retinopathy, Macular degeneration.
* Neurological \& Non-Glaucomatous causes for Visual Field damage.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NYU Langone Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gadi Wollstein, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO15070113
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.